** Healthcare stocks trade heavily in the red, accountingfor more than half of the FTSE 100's points drop.
** UK benchmark down 0.3 pct.
** AstraZeneca falls 2.5 pct even after raising its2014 sales forecast.
** Traders said drugmaker's results would have needed tohave been quite dramatic to have boosted stock, already tradingaround levels last seen before it saw off a $118 bln takeoverbid from Pfizer in May.
** Share price weakness trims YTD gains to about 26 pct.
** AstraZeneca CEO says recent U.S. tax changes weaken casefor new Pfizer bid.
** GlaxoSmithKline down 2.3 pct as tradesex-dividend.
** Smith & Nephew pares back gains after strong runaround recent robust results.
** Ed Woolfitt, head of trading at Galvan sees S&N weaknessas decent buying opportunity. (RM: tricia.wright1.thomsonreuters.com@reuters.net)